{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:39:55Z","timestamp":1792093195437,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejca.2025.115337","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T11:26:35Z","timestamp":1741001195000},"page":"115337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapy"],"prefix":"10.1016","volume":"220","author":[{"given":"Philipp","family":"Jansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Galetzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9882-4344","authenticated-orcid":false,"given":"Carl M.","family":"Thielmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajmohan","family":"Murali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Zaremba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6699-8377","authenticated-orcid":false,"given":"Fabian","family":"Standl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6930-2694","authenticated-orcid":false,"given":"Georg","family":"Lodde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2753-9626","authenticated-orcid":false,"given":"Antje","family":"Sucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Paschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3680-3521","authenticated-orcid":false,"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8279-9239","authenticated-orcid":false,"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Stang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3899-9449","authenticated-orcid":false,"given":"Klaus G.","family":"Griewank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10151","key":"10.1016\/j.ejca.2025.115337_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejca.2025.115337_bib2","doi-asserted-by":"crossref","first-page":"500","DOI":"10.5858\/arpa.2019-0561-RA","article-title":"The 2018 world health organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway","volume":"144","author":"Elder","year":"2020","journal-title":"Arch Pathol Lab Med"},{"issue":"20","key":"10.1016\/j.ejca.2025.115337_bib3","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2025.115337_bib4","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/ng.2359","article-title":"Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma","volume":"44","author":"Krauthammer","year":"2012","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.ejca.2025.115337_bib5","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Cancer genome Atlas N. genomic classification of cutaneous melanoma","volume":"161","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2025.115337_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114208","article-title":"Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS-and NF1-(\u201cTriple\u201d) wild type melanomas","author":"Jansen","year":"2024","journal-title":"Eur J Cancer"},{"issue":"6122","key":"10.1016\/j.ejca.2025.115337_bib7","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","article-title":"TERT promoter mutations in familial and sporadic melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"issue":"6122","key":"10.1016\/j.ejca.2025.115337_bib8","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent TERT promoter mutations in human melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.ejca.2025.115337_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju246","article-title":"TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma","volume":"106","author":"Griewank","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ejca.2025.115337_bib10","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjd.19297","article-title":"Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients","volume":"184","author":"Manrique-Silva","year":"2021","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115337_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ijc.30042","article-title":"TERT promoter mutations in melanoma survival","volume":"139","author":"Nagore","year":"2016","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2025.115337_bib12","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jid.2019.06.149","article-title":"Classifying melanoma by TERT promoter mutational status","volume":"140","author":"Shaughnessy","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"20","key":"10.1016\/j.ejca.2025.115337_bib13","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ejca.2025.115337_bib14","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115337_bib15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"10.1016\/j.ejca.2025.115337_bib16","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2025.115337_bib17","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2025.115337_bib18","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ejca.2025.115337_bib19","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"6280","key":"10.1016\/j.ejca.2025.115337_bib20","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"issue":"6230","key":"10.1016\/j.ejca.2025.115337_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.ejca.2025.115337_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15112888","article-title":"TERT expression induces resistance to BRAF and MEK inhibitors in BRAF-mutated melanoma in vitro","volume":"15","author":"Delyon","year":"2023","journal-title":"Cancers"},{"issue":"27","key":"10.1016\/j.ejca.2025.115337_bib23","doi-asserted-by":"crossref","first-page":"15846","DOI":"10.1073\/pnas.2004707117","article-title":"TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles heel","volume":"117","author":"Tan","year":"2020","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"10.1016\/j.ejca.2025.115337_bib24","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.3390\/cancers12082224","article-title":"TERT promoter mutation as an independent prognostic marker for poor prognosis MAPK inhibitors-treated melanoma","volume":"12","author":"Blateau","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2025.115337_bib25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.11.009","article-title":"TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy","volume":"161","author":"Thielmann","year":"2022","journal-title":"Eur J Cancer"},{"issue":"9318","key":"10.1016\/j.ejca.2025.115337_bib26","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/S0140-6736(02)08594-X","article-title":"Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls","volume":"359","author":"Pocock","year":"2002","journal-title":"Lancet"},{"issue":"36","key":"10.1016\/j.ejca.2025.115337_bib27","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.115337_bib28","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2025.115337_bib29","series-title":"A Language and Environment for Statistical Computing","author":"Team RC","year":"2020"},{"key":"10.1016\/j.ejca.2025.115337_bib30","series-title":"Integrated Development for R. Studio","author":"Team","year":"2019"},{"issue":"5","key":"10.1016\/j.ejca.2025.115337_bib31","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/pcmr.12500","article-title":"High TERT promoter mutation frequency in non-acral cutaneous metastatic melanoma","volume":"29","author":"Ekedahl","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"issue":"26","key":"10.1016\/j.ejca.2025.115337_bib32","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"30","key":"10.1016\/j.ejca.2025.115337_bib33","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1200\/JCO.23.01136","article-title":"Systemic therapy for melanoma: ASCO guideline update","volume":"41","author":"Seth","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115337_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103288","article-title":"TERT promoter mutations and melanoma survival: a comprehensive literature review and meta-analysis","volume":"160","author":"Gandini","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.ejca.2025.115337_bib35","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1200\/PO.21.00084","article-title":"Positive association between location of melanoma, ultraviolet signature, tumor mutational burden, and response to anti\u2013PD-1 therapy","author":"Dousset","year":"2021","journal-title":"JCO Precis Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T18:45:41Z","timestamp":1760640341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925001182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":35,"alternative-id":["S0959804925001182"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115337","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115337"}}